SE
MCID: STT001
MIFTS: 59

Status Epilepticus (SE)

Categories: Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Status Epilepticus

MalaCards integrated aliases for Status Epilepticus:

Name: Status Epilepticus 11 19 28 53 5 43 14 16 71 75 31 33
Grand Mal Status Epilepticus 71 31
Generalized Convulsive Status Epilepticus 19
Epilepsy with Status Epilepticus 33
Grand Mal Status 11
Gcse 19
Se 19

Classifications:



External Ids:

Disease Ontology 11 DOID:1824
MeSH 43 D013226
NCIt 49 C85079
SNOMED-CT 68 155039002
ICD10 31 G41 G41.0 G41.9
UMLS 71 C0038220 C0311335

Summaries for Status Epilepticus

GARD: 19 A life-threatening situation in which the brain is in a continuous state of seizure.

MalaCards based summary: Status Epilepticus, also known as grand mal status epilepticus, is related to epilepsy, pyridoxine-dependent and lennox-gastaut syndrome, and has symptoms including seizures and symptomatic seizures. An important gene associated with Status Epilepticus is GALC (Galactosylceramidase), and among its related pathways/superpathways are Neuropathic Pain-Signaling in Dorsal Horn Neurons and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Clonazepam and Paraldehyde have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and amygdala, and related phenotypes are nervous system and normal

Wikipedia: 75 Status epilepticus (SE) is a single seizure lasting more than 5 minutes or 2 or more seizures within a... more...

Related Diseases for Status Epilepticus

Diseases related to Status Epilepticus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1001)
# Related Disease Score Top Affiliating Genes
1 epilepsy, pyridoxine-dependent 32.4 SCN1A PCDH19 KCNQ2
2 lennox-gastaut syndrome 32.2 SCN1A PCDH19 KCNQ2 GRIN2B
3 generalized epilepsy with febrile seizures plus 32.1 SCN1A PVALB PCDH19 LGI1 KCNQ2
4 dravet syndrome 32.1 SCN1A PVALB PCDH19 LGI1 KCNQ2 GRIN2B
5 temporal lobe epilepsy 31.7 PVALB NPY LGI1 GRIN2B GFAP CALB1
6 neonatal hypoxic and ischemic brain injury 31.5 PVALB ENO2 BDNF
7 limbic encephalitis 31.3 LGI1 GRIN2B GRIA1
8 early myoclonic encephalopathy 31.3 SCN1A POLG PCDH19 LGI1 KCNQ2
9 toxic encephalopathy 31.2 JUN GRIN2B GRIA1 GFAP BDNF
10 epilepsy 31.2 SCN1A PVALB POLG PCDH19 NPY LGI1
11 focal epilepsy 31.2 SCN1A PVALB PCDH19 NPY LGI1 KCNQ2
12 epilepsy, idiopathic generalized 31.1 SCN1A PVALB PCDH19 LGI1 KCNQ2
13 landau-kleffner syndrome 31.1 SCN1A PCDH19 KCNQ2 GRIN2B
14 epilepsy, myoclonic juvenile 31.0 SCN1A PVALB PCDH19 LGI1 KCNQ2
15 movement disease 31.0 POLG LGI1 GFAP BDNF
16 alcohol use disorder 31.0 NPY GRIN2B BDNF
17 amnestic disorder 31.0 LGI1 GRIN2B GRIA1 FOS BDNF
18 childhood absence epilepsy 30.9 SCN1A PVALB PCDH19 LGI1 KCNQ2 GRIN2B
19 benign epilepsy with centrotemporal spikes 30.8 SCN1A PCDH19 LGI1 KCNQ2 GRIN2B
20 hydrocephalus 30.8 NPY GFAP ENO2 BDNF
21 headache 30.8 SCN1A NPY BDNF
22 autism spectrum disorder 30.8 SCN1A PCDH19 GRIN2B GRIA2 GRIA1 GFAP
23 progressive myoclonus epilepsy 30.7 SCN1A PCDH19 KCNQ2
24 akinetic mutism 30.7 LGI1 ENO2
25 speech and communication disorders 30.7 LGI1 GRIN2B GFAP BDNF
26 psychotic disorder 30.7 PVALB NPY GRIN2B GRIA2 GRIA1 FOS
27 west syndrome 30.7 SCN1A PVALB POLG PCDH19 NPY LGI1
28 withdrawal disorder 30.7 GRIN2B FOS BDNF
29 anxiety 30.7 NPY GRIN2B GRIA1 FOS BDNF
30 anterograde amnesia 30.6 LGI1 FOS BDNF
31 dystonia 30.6 PVALB POLG NPY GRIN2B BDNF
32 encephalomalacia 30.6 GFAP GALC BDNF
33 major depressive disorder 30.5 PVALB NPY GRIA1 FOS BDNF
34 partial motor epilepsy 30.5 SCN1A POLG PCDH19 LGI1 KCNQ2
35 ganglioglioma 30.5 PVALB GFAP ENO2
36 choreatic disease 30.5 PVALB POLG LGI1 GRIN2B BDNF
37 early infantile epileptic encephalopathy 30.4 TRAK1 SCN1A PCDH19 KCNQ2 GRIN2B
38 bipolar disorder 30.4 PVALB POLG GRIN2B GRIA2 GRIA1 GFAP
39 epilepsy with generalized tonic-clonic seizures 30.4 SCN1A PCDH19 KCNQ2
40 speech disorder 30.4 PVALB LGI1 GRIN2B CALB1
41 sleep disorder 30.4 NPY FOS BDNF
42 migraine with or without aura 1 30.4 SCN1A POLG NPY KCNQ2 GRIN2B GRIA1
43 attention deficit-hyperactivity disorder 30.4 SCN1A PVALB NPY GRIN2B GRIA2 GRIA1
44 fragile x syndrome 30.4 GRIN2B GRIA2 GRIA1 BDNF
45 episodic ataxia 30.4 SCN1A LGI1 KCNQ2
46 developmental and epileptic encephalopathy 30.3 TRAK1 SCN1A PVALB POLG PCDH19 LGI1
47 optic nerve disease 30.3 POLG LGI1 JUN GFAP BDNF
48 substance abuse 30.3 NPY GRIN2B FOS BDNF
49 wernicke-korsakoff syndrome 30.3 PVALB CALB1 BDNF
50 pertussis 30.3 NPY JUN FOS

Comorbidity relations with Status Epilepticus via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Alzheimer Disease, Familial, 1
Bronchitis Cerebral Atherosclerosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Status Epilepticus:



Diseases related to Status Epilepticus

Symptoms & Phenotypes for Status Epilepticus

UMLS symptoms related to Status Epilepticus:


seizures; symptomatic seizures

MGI Mouse Phenotypes related to Status Epilepticus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.23 BDNF CALB1 ENO2 FOS GALC GAP43
2 normal MP:0002873 10.07 BDNF CALB1 FOS GFAP GRIA1 GRIA2
3 growth/size/body region MP:0005378 10.03 BDNF ENO2 FOS GALC GAP43 GFAP
4 behavior/neurological MP:0005386 9.89 BDNF CALB1 ENO2 FOS GALC GFAP
5 no phenotypic analysis MP:0003012 9.87 BDNF GRIA1 GRIA2 GRIN2B JUN POLG
6 mortality/aging MP:0010768 9.5 BDNF FOS GALC GAP43 GFAP GRIA2

Drugs & Therapeutics for Status Epilepticus

Drugs for Status Epilepticus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 3 1622-61-3 2802
2
Paraldehyde Approved, Investigational Phase 3 123-63-7 31264
3
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
4
Ganaxolone Approved, Investigational Phase 3 38398-32-2 22023730 6918305
5
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
6
Topiramate Approved Phase 3 97240-79-4 5284627
7
Alprazolam Approved, Illicit, Investigational Phase 3 28981-97-7 2118
8
Thiopental Approved, Vet_approved Phase 3 76-75-5 3000715
9
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 439-14-5 3016
10
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5, 1424-27-7 1986
11
Pentobarbital Approved, Investigational, Vet_approved Phase 3 76-74-4 4737
12 Pharmaceutical Solutions Phase 3
13 Psychotropic Drugs Phase 2, Phase 3
14 Anti-Anxiety Agents Phase 2, Phase 3
15 Gastrointestinal Agents Phase 2, Phase 3
16 Antiemetics Phase 2, Phase 3
17 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
18 diuretics Phase 2, Phase 3
19
Coal tar Approved Phase 1, Phase 2 8007-45-2
20
Vigabatrin Approved Phase 2 60643-86-9, 68506-86-5 5665
21 Strawberry Approved Phase 1
22
Cannabidiol Approved, Investigational Phase 1 13956-29-1 521372 644019
23
Ethanol Approved Phase 1 64-17-5 702
24
Racepinephrine Approved, Vet_approved 51-43-4, 329-65-7 838 5816
25
Clobazam Approved, Illicit 22316-47-8 2789
26
Eltanolone Approved, Investigational 516-54-1, 128-20-1 31402 92786
27
Sage Approved
28 Liver Extracts
29 Epinephryl borate
30 GABA Agonists
31 Neurosteroids

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus: a Randomized Clinical Trial Unknown status NCT04176887 Phase 4 Levetiracetam Injection;Phenytoin Injection
2 Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus Recruiting NCT04829838 Phase 4 intravenous levetireacetam
3 Efficacy of add-on PEramPanel in Focal Motor Status Epilepticus Unknown status NCT04309721 Phase 3 Perampanel;Placebo
4 Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility Completed NCT01586208 Phase 3 valproic acid (VPA)
5 A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus Completed NCT02239380 Phase 3 Lorazepam
6 Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial Completed NCT00735527 Phase 3 Lorazepam
7 Childhood Convulsive Status Epilepticus - In Search Of Optimal Drug Management In A Resource Limited Setting Completed NCT03650270 Phase 3 Phenobarbital
8 A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics Completed NCT00809146 Phase 3 Intramuscular route of active treatment;Intravenous route of active treatment
9 Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus Completed NCT01150331 Phase 3 Levetiracetam/Clonazepam;Clonazepam/Placebo levetiracetam IV
10 Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam Completed NCT00621478 Phase 2, Phase 3 lorazepam or diazepam
11 A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children Completed NCT00116064 Phase 3 intranasal lorazepam;intramuscular paraldehyde
12 A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room Completed NCT03336645 Phase 3 SHP615
13 A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings Completed NCT03336450 Phase 3 SHP615;MHOS/SHP615
14 Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Completed NCT00004297 Phase 3 diazepam;lorazepam
15 A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus. Completed NCT01960075 Phase 3 Fosphenytoin;Levetiracetam;Valproic acid
16 Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients Completed NCT01870024 Phase 3 Clonazepam;Fosphenytoin;Placebo;Lorazepam
17 Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study Completed NCT01359332 Phase 3
18 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus Completed NCT02477618 Phase 3 SAGE-547;Placebo
19 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus Recruiting NCT04391569 Phase 3 Ganaxolone;Placebo
20 A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Recruiting NCT05077904 Phase 3 Staccato alprazolam
21 Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. Recruiting NCT05346666 Phase 3 Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
22 Efficacy of Lacosamide in Neonatal Status Epilepticus: A Randomized Controlled Study Recruiting NCT05291455 Phase 3 Lacosamide;Phenobarbital
23 Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) Recruiting NCT05263674 Phase 3 Rapid sedation
24 An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Enrolling by invitation NCT05076617 Phase 3 Staccato alprazolam
25 Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS) Terminated NCT02904265 Phase 2, Phase 3 Diazepam;Acetazolamide
26 Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial Terminated NCT00343096 Phase 3 Lorazepam
27 A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus Terminated NCT00265616 Phase 3 propofol;thiopental/pentobarbital
28 Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study. Terminated NCT02431663 Phase 3 Ketamine
29 Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus Withdrawn NCT02726867 Phase 3 levetiracetam;lacosamide;Ketamine;Phenobarbital
30 Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study Withdrawn NCT03115489 Phase 2, Phase 3 Traditional Treatment (Group T);Ketamine Infusion (Group K)
31 Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China Unknown status NCT03025906 Phase 2 Phenobarbital;Valproate
32 Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus Unknown status NCT00362141 Phase 2 levetiracetam (add-on)
33 Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children Completed NCT04926844 Phase 2 Levetiracetam;Midazolam;Placebo
34 A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus Completed NCT03350035 Phase 2 IV Ganaxolone active;IV Placebo, non-active
35 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
36 An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Completed NCT02052739 Phase 1, Phase 2 SAGE-547
37 VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa Recruiting NCT04772547 Phase 2 Vigabatrin Only Product
38 Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus Withdrawn NCT00603135 Phase 2 first-line i/v-levetiracetam
39 Phase 1, Open-Label, Comparison Study to Evaluate the Safety and Pharmacokinetics of a Single Intramuscular Administration of 10 mg Midazolam Using an Auto-Injector vs Marketed Midazolam Vials in Healthy Adults. Completed NCT04679623 Phase 1 Seizalam
40 Use of Lorazepam for the Treatment of Status Epilepticus Completed NCT00114569 Phase 1 lorazepam
41 Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). Recruiting NCT04721691 Phase 1 Epidiolex 100 mg/mL Oral Solution
42 Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures Unknown status NCT01268904 Valproate
43 A Multi-center Clinical Study of Children With Status Epilepticus in China Unknown status NCT03378687
44 Management of Non Convulsive Status Epilepticus Unknown status NCT03245099
45 Management Strategies for Electrical Status Epilepticus During Sleep Unknown status NCT03251820 corticosteroid
46 Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus Unknown status NCT02344706
47 Feasibility and Tolerability of the Ketogenic Diet in the Treatment of Refractory Status Epilepticus in a Neurointensive Care Unit. Completed NCT01796574
48 Smartphone Medical Applications to Reduce Treatment Dosage Errors in Pediatric Resuscitation; a Randomized Simulation Trial Completed NCT02958605
49 TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation Completed NCT02056236 Anti-epileptic drugs
50 Does Use of Rapid Response EEG Impact Clinical Decision Making Completed NCT03534258

Search NIH Clinical Center for Status Epilepticus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amobarbital
AMOBARBITAL NA PWDR
Amobarbital Sodium
Diazepam
Etomidate
fosphenytoin
Fosphenytoin sodium
Lorazepam
Midazolam
Midazolam Hydrochloride
Pentobarbital
PENTOBARBITAL NA PWDR
Pentobarbital Sodium
Propofol

Cochrane evidence based reviews: status epilepticus

Genetic Tests for Status Epilepticus

Genetic tests related to Status Epilepticus:

# Genetic test Affiliating Genes
1 Status Epilepticus 28

Anatomical Context for Status Epilepticus

Organs/tissues related to Status Epilepticus:

MalaCards : Brain, Temporal Lobe, Amygdala, Cortex, Bone Marrow, Liver, Occipital Lobe

Publications for Status Epilepticus

Articles related to Status Epilepticus:

(show top 50) (show all 13990)
# Title Authors PMID Year
1
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. 53 62
20138553 2010
2
Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. 53 62
20004712 2010
3
The unfolding clinical spectrum of POLG mutations. 53 62
19578034 2009
4
Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. 53 62
18595663 2008
5
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 53 62
18294203 2008
6
Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. 53 62
18177354 2008
7
Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. 53 62
17727632 2007
8
Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. 53 62
16901909 2006
9
Histone modifications in status epilepticus induced by kainate. 53 62
16598677 2006
10
Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. 53 62
16469864 2006
11
Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. 53 62
16091474 2005
12
Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. 53 62
15191797 2004
13
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. 53 62
14689039 2004
14
Transient downregulation of Sema3A mRNA in a rat model for temporal lobe epilepsy. A novel molecular event potentially contributing to mossy fiber sprouting. 53 62
12821384 2003
15
Serum neuron-specific enolase in children with febrile seizures: time profile and prognostic implications. 53 62
12767459 2003
16
Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures. 53 62
11166790 2001
17
Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. 53 62
10531425 1999
18
Serum neuron-specific enolase in the major subtypes of status epilepticus. 53 62
10078721 1999
19
Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. 53 62
9595992 1998
20
Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss. 53 62
9825961 1998
21
Serum NSE in status epilepticus. 53 62
8649598 1996
22
The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. 53 62
9246466 1996
23
Serum neuron-specific enolase in human status epilepticus. 53 62
7783877 1995
24
Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischaemic brain injury? 53 62
8326831 1993
25
Activation of metabotropic glutamate receptor 1 regulates hippocampal CA1 region excitability in rats with status epilepticus by suppressing the HCN1 channel. 62
36018183 2023
26
Long-term outcome of convulsive status epilepticus: a 10-year follow-up 62
35993832 2022
27
Classification of electrical status epilepticus in sleep based on EEG patterns and spatiotemporal mapping of spikes 62
36125364 2022
28
Yield and risk associated with prolonged presurgical video-EEG monitoring: a systematic review 62
36039766 2022
29
Protective Effect of Tilia americana var. mexicana Against Kainic Acid-induced Damage in Brain, Liver, and Kidney: Behavioral and Biochemical Changes. 62
36060909 2022
30
An epilepsy curriculum for primary health care providers: a report from the Education Council of the International League Against Epilepsy 62
35993831 2022
31
Location-atypical lesions in non-ketotic hyperglycemic epilepsy: expanding the clinico-radiographic phenotype 62
36193019 2022
32
Status Epilepticus Related Takotsubo Syndrome - A Case Report. 62
35470412 2022
33
Vitamin D deficiency in British South Asians, a persistent but avoidable problem associated with many health risks (including rickets, T2DM, CVD, COVID-19 and pregnancy complications): the case for correcting this deficiency. 62
36149836 2022
34
Status epilepticus during the COVID-19 pandemic in Cologne, Germany: data from a retrospective, multicentre registry. 62
35802201 2022
35
Dietary Treatments for Epilepsy. 62
36270691 2022
36
Post-COVID-19 Immune-Mediated Neurological Complications in Children: An Ambispective Study. 62
36049379 2022
37
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis. 62
36266054 2022
38
Clinico-biological markers for the prognosis of status epilepticus in adults. 62
35768546 2022
39
Rescue Treatments for Seizure Clusters. 62
36270699 2022
40
Paeonol exerts neuroprotective and anticonvulsant effects in intrahippocampal kainate model of temporal lobe epilepsy. 62
35718291 2022
41
Cumulative effects of antiseizure medication on intelligence in children with focal epilepsy 62
35904036 2022
42
Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications 62
35894673 2022
43
Epilepsy management during difficult times 62
35816097 2022
44
LncRNA ZFAS1 regulates the hippocampal neurons injury in epilepsy through the miR-15a-5p/OXSR1/NF-κB pathway. 62
35751788 2022
45
Management of epilepsy in older adults: A critical review by the ILAE Task Force on Epilepsy in the elderly. 62
36266921 2022
46
De novo Y1460C missense variant in NaV1.1 impedes the pore region and results in epileptic encephalopathy. 62
36229510 2022
47
Multi-omic Analysis of the Gut Microbiome in Rats with Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy. 62
35962889 2022
48
Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. 62
35975599 2022
49
Enhanced excitability of the hippocampal CA2 region and its contribution to seizure activity in a mouse model of temporal lobe epilepsy. 62
35987207 2022
50
Opportunities for Community Pharmacists to Counsel Patients With Epilepsy and Seizure Clusters to Overcome Barriers and Foster Appropriate Treatment. 62
36193947 2022

Variations for Status Epilepticus

ClinVar genetic disease variations for Status Epilepticus:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GALC NM_000153.4(GALC):c.196G>A (p.Ala66Thr) SNV Likely Pathogenic
374023 rs1057518843 GRCh37: 14:88454867-88454867
GRCh38: 14:87988523-87988523
2 GALC NM_000153.4(GALC):c.850G>A (p.Gly284Ser) SNV Likely Pathogenic
374024 rs377274761 GRCh37: 14:88434737-88434737
GRCh38: 14:87968393-87968393
3 SRRM2 NM_016333.4(SRRM2):c.6777_6778del (p.Arg2260fs) MICROSAT Likely Pathogenic
1707520 GRCh37: 16:2817303-2817304
GRCh38: 16:2767302-2767303
4 overlap with 4 genes GRCh37/hg19 Xp22.31(chrX:6624655-7894210)x1 CN LOSS Uncertain Significance
1330205 GRCh37: X:6624655-7894210
GRCh38:

Expression for Status Epilepticus

Search GEO for disease gene expression data for Status Epilepticus.

Pathways for Status Epilepticus

Pathways related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 SCN1A GRIN2B GRIA2 GRIA1 FOS BDNF
2 12.14 KCNQ2 GRIN2B GRIA2 GRIA1
3
Show member pathways
12.11 PVALB GRIN2B GRIA2 BDNF
4 11.85 SCN1A NPY KCNQ2 GRIN2B GRIA2 GRIA1
5
Show member pathways
11.8 GRIN2B GRIA2 GRIA1 BDNF
6 11.73 BDNF FOS GAP43 GFAP
7
Show member pathways
11.68 GRIN2B GRIA2 GRIA1
8
Show member pathways
11.65 GRIN2B GRIA2 GRIA1
9 11.58 GRIN2B GRIA2 GRIA1 GFAP FOS BDNF
10 11.57 GFAP GALC BDNF
11 11.26 JUN FOS CALB1
12 10.99 PVALB KCNQ2 GRIN2B CALB1
13 10.9 GRIN2B GRIA2 GRIA1
14 10.77 JUN FOS
15 10.73 JUN FOS
16 10.62 JUN FOS
17 10.55 JUN FOS

GO Terms for Status Epilepticus

Cellular components related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 10.1 TRAK1 GRIA2 GRIA1 GAP43 CALB1 BDNF
2 synaptic membrane GO:0097060 9.85 GRIN2B GRIA1 ENO2
3 neuron projection GO:0043005 9.81 CALB1 ENO2 FOS GRIA1 GRIN2B NPY
4 neuronal cell body GO:0043025 9.7 SCN1A PVALB GRIA2 GRIA1 ENO2 CALB1
5 transcription factor AP-1 complex GO:0035976 9.56 JUN FOS
6 synapse GO:0045202 9.36 PVALB LGI1 KCNQ2 GRIN2B GRIA2 GRIA1

Biological processes related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.02 NPY KCNQ2 GRIN2B GRIA2 GRIA1
2 ion transmembrane transport GO:0034220 9.8 SCN1A KCNQ2 GRIN2B GRIA2 GRIA1
3 ionotropic glutamate receptor signaling pathway GO:0035235 9.63 GRIN2B GRIA2 GRIA1
4 glutamate receptor signaling pathway GO:0007215 9.26 GRIN2B GRIA2 GRIA1
5 regulation of presynaptic membrane potential GO:0099505 8.8 SCN1A GRIN2B GRIA1

Molecular functions related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ligand-gated ion channel activity GO:0015276 9.63 GRIN2B GRIA2 GRIA1
2 AMPA glutamate receptor activity GO:0004971 9.56 GRIA2 GRIA1
3 ionotropic glutamate receptor activity GO:0004970 9.26 GRIN2B GRIA2 GRIA1
4 ion channel activity GO:0005216 9.02 SCN1A KCNQ2 GRIN2B GRIA2 GRIA1

Sources for Status Epilepticus

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....